38 results about "Cranial nerve disease" patented technology

Intravenous administration of bone marrow cells collected from rat bone marrow to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases.

Intravenous administration of bone marrow cells collected from rat bone marrow or peripheral blood to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases.

The invention discloses a dual-channel product for preventing and treating encephalopathy. The product comprises nervonic acid and phosphatidylserine according to the mass ratio of being (1-9):(1-9). The preparation method comprises the following steps: (a) compounding according to the mass ratio of raw materials; (b) grinding and degassing; (c) preparing a capsule material; (d) pelleting; (e) molding and drying; (f) pellet washing; (g) selecting and screening; (h) packaging. The invention further discloses an application of the dual-channel product in the preparation of a product for treating a cranial nerve disease. The product can be used for synchronously treating cranial nerve cells and nerve fibers, thereby taking a comprehensive effect on the encephalopathy and having an obvious effect. In addition, the product is natural purely and safe to eat, and can be absorbed completely as well as cannot generate toxic and side effects. The preparation method is reasonable in process and strong in operability, thereby being suitable for large-scale industrial production.

The invention relates to the technical field of biology and discloses a colonization probiotic preparation and application and medicines thereof. The colonization probiotic preparation is used for directly acting on the respiratory mucosa and comprises a surfactant and probiotics. By the surfactant, modification of a sol layer and a gel layer of respiratory tract mucus is realized, probability and speed in contact of the probiotics with respiratory mucosa cells are increased, cell surface hydrophobicity of the probiotics is changed, an adhesion rate of the probiotics and respiratory mucosa epithelial cells is increased, and accordingly the technical bottleneck of difficulty in colonization of the probiotics to the respiratory mucosa under expelling action of a mucociliary transmission system is solved. The colonization probiotic preparation can be applied to fields of preparation of medicines for treatment of rhinitis, treatment of asthma, treatment of allergic dermatitis or treatment of cranial nerve diseases, anti-nasopharynx-cancer, anti-lung-cancer or anti-cold medicines or medicines for prevention or treatment of respiratory infectious diseases.

The present invention relates to stem cells in which a gene that activates signaling is introduced and to a method for proliferating the stem cells. More specifically, the invention relates to a method of significantly increasing the ability of stem cells to proliferate, either by transfecting stem cells with the Notch intracellular domain (NICD) to activate the Notch signaling pathway, or by transfecting stem cells with the c-MET gene and treating the transfected stem cells with the HGF ligand protein to activate the c-MET / HGF signaling pathway. According to the present invention, as a result of activating the Notch signaling pathway or the c-MET / HGF signaling pathway, stem cells having an excellent ability to proliferate can be produced in large amounts. Particularly, since neural stem cells which have been difficult to culture in vitro can be proliferated in large amounts, thus the neural stem cells will be more useful for the preparation of cell therapeutic agents for treating cranial nerve diseases.

Intravenous administration of bone marrow cells collected from rat bone marrow or peripheral blood to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases.

The invention discloses a dynamic function mode learning method enlightened by a fMRI brain network mechanism. The method comprises the steps of acquiring resting state fMRI brain image data of a plurality of testees; performing preprocessing operation on the resting state fMRI brain image data; according to the preprocessed resting state fMRI brain image data, respectively acquiring resting state brain function networks in a group level and an individual level and the corresponding time sequences by means of a GICA-IR method; calculating a dynamic function connecting matrix between the corresponding resting state brain function networks of the testees by means of a sliding time window method, converting a triangle element on the dynamic function connecting matrix to a dynamic function connecting vector, and furthermore acquiring a dynamic function connecting vector set which corresponds with all testees; and extracting a brain inherent dynamic function connecting mode which is hidden in the dynamic function connecting vector set by means of a deep neural network model and an affine propagation clustering algorithm. The dynamic function mode learning method supplies a solid basis for discovering a basic principle of brain cognition activities, a damage mechanism of cranial nerve diseases and researching a career cerebral plasticity recombination characteristic, etc.

A canine hepatocyte growth factor gene and a 15 base pairs-deleted gene thereof encode a protein having an amino acid sequence shown in SEQ ID NO: 2 or 4 and a protein having an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids and having a canine hepatocyte growth factor activity. The canine hepatocyte growth factor and the 5 amino acids-deleted canine hepatocyte growth factor are useful for the treatment of liver diseases, kidney diseases, lung diseases, digestive diseases, cardiocirculatory diseases or cranial nerve diseases.

The invention belongs to the technical field of medicines, and discloses an alprostadil lipid nanosphere injection and a preparation method thereof. The alprostadil lipid nanosphere injection is prepared from the following raw materials in parts by weight: 0.002-0.2 part of alprostadil, 40-100 parts of oil for injection, 20-40 parts of emulsifier, 25-50 parts of cosurfactant, 20-30 parts of glycerol, and 780-890 parts of water. The alprostadil lipid nanosphere injection provided by the invention has the particle size smaller than 100 nm, can be sterilized by aseptic filtration, overcomes the instability shortcoming of alprostadil, and improves product stability. Meanwhile, the lipid nanosphere has the particle size smaller than 100 nm, so that the alprostadil lipid nanosphere injection is more favorable for in vivo non-resveratrol (RES) tissue distribution of alprostadil, reduction of pulmonary circulation inactivation and blood removal, and long-term in vivo circulation of alprostadil. The alprostadil lipid nanosphere injection is suitable for surgical treatment of heart diseases and cranial nerve diseases.

The present invention relates to a novel quinazoline-2,4-dione derivative of formula (I), a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising a compound of formula (I) as an active ingredient for preventing or treating neurological brain disease.

The invention discloses Danshensu derivatives as well as a preparation method and medical application thereof. The derivatives have a general structure as shown in a general formula (I) shown in the specification, wherein R1 represents OH or OCH3; R2 represents H or Ac; and R3 represents a first structure, a second structure or a third structure shown in the specification. Compared with a raw material medicine, the derivatives synthesized by the invention have the advantages that the fat solubility is increased, so that the derivatives can penetrate through the blood-brain barrier (BBB), the medicine stability is greatly improved, and the curative effect is further improved. Therefore, the derivatives disclosed by the invention can be applied to preparation of drugs for preventing, treating, treating and / or reducing the cerebral infarction volume of a patient, improving the balance coordination ability of the patient and other diseases, and a new therapeutic drug is provided for preventing and treating cerebrovascular or cranial nerve diseases.

The present invention relates to a method for producing cholinergic neurons comprising obtaining neural progenitor cells from stem cells so as to continuously produce cholinergic neural cells with high purity and the same traits, followed by differentiating the neural progenitor cells into the cholinergic neurons, and cholinergic neurons produced therefrom. Since the method of preparing the cholinergic neurons provided in the present invention enables not only production of the cholinergic neurons with high purity, but also rapid production of the cholinergic neurons with the same traits, it can be widely used for effectively treating degenerative cranial nerve diseases such as Alzheimer's disease.

Disclosed is a pharmaceutical composition containing a compound useful for inhibiting neurotoxicity caused by beta amyloid. The pharmaceutical composition of the present disclosure contains 1,3,5,7-tetrakis(aminomethyl)adamantane, an analogous compound thereof or a salt thereof as an active ingredient. The inventors have studied methods for reducing the toxicity of beta amyloid oligomers based on the formation mechanism of dodecamers in consideration of the fact that especially the dodecamers from among the beta amyloid oligomers exhibit a significant activity as a toxin for synapses and neurons in cranial nerve diseases. The inventors have confirmed that the disclosed compound can induce structural epitope deformation of the dodecamer and thereby reduce toxicity of the beta amyloid oligomers. The pharmaceutical composition containing the compound is useful for preventing and treating cranial nerve diseases developed by the toxicity of beta amyloid oligomers, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, macular degeneration, prion disease, and the like (see FIG. 1).

The present invention relates to stem cells in which a gene that activates signaling is introduced and to a method for proliferating the stem cells. More specifically, the invention relates to a method of significantly increasing the ability of stem cells to proliferate, either by transfecting stem cells with the Notch intracellular domain (NICD) to activate the Notch signaling pathway, or by transfecting stem cells with the c-MET gene and treating the transfected stem cells with the HGF ligand protein to activate the c-MET / HGF signaling pathway. According to the present invention, as a result of activating the Notch signaling pathway or the c-MET / HGF signaling pathway, stem cells having an excellent ability to proliferate can be produced in large amounts. Particularly, since neural stem cells which have been difficult to culture in vitro can be proliferated in large amounts, thus the neural stem cells will be more useful for the preparation of cell therapeutic agents for treating cranial nerve diseases.

The invention provides a production method for preparing a substance taking plasmalogen as an effective ingredient and being used for treating cranial nerve diseases from biological materials.The production method comprises the processes that 1, the biological materials are extracted through mixed solvent of aliphatic hydrocarbon solvent and water-soluble ketone solvent; 2, an insoluble part obtained in the process 1 is washed with the mixed solvent of the aliphatic hydrocarbon solvent and the water-soluble ketone solvent to obtain crude plasmalogen; 3, a soluble part obtained in the process 1 is treated to obtain crude plasmalogen; 4, a glycerol phosphatide hydrolase-phospholipase acts with the crude plasmalogen obtained in the process 2 to obtain the plasmalogen; 5, the glycerol phosphatide hydrolase-phospholipase acts with the crude plasmalogen obtained in the process 3 to obtain the plasmalogen.The purity of the effective ingredient plasmalogen of the medicine prepared through the method is high, and the plasmalogen is an ingredient contained in biological tissue, so that the preparation safety is very high.

The present invention relates to stem cells in which a gene that activates signaling is introduced and to a method for proliferating the stem cells. More specifically, the invention relates to a method of significantly increasing the ability of stem cells to proliferate, either by transfecting stem cells with the Notch intracellular domain (NICD) to activate the Notch signaling pathway, or by transfecting stem cells with the c-MET gene and treating the transfected stem cells with the HGF ligand protein to activate the c-MET / HGF signaling pathway. According to the present invention, as a result of activating the Notch signaling pathway or the c-MET / HGF signaling pathway, stem cells having an excellent ability to proliferate can be produced in large amounts. Particularly, since neural stem cells which have been difficult to culture in vitro can be proliferated in large amounts, thus the neural stem cells will be more useful for the preparation of cell therapeutic agents for treating cranial nerve diseases.

A canine hepatocyte growth factor gene and a 15 base pairs-deleted canine hepatocyte growth factor gene. These genes encode the following protein (a) or (b): (a) a protein having an amino acid sequence shown in SEQ ID NO: 2 or 4; and (b) a protein having an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 2 or 4, and having a canine hepatocyte growth factor activity. The canine hepatocyte growth factor and the 5 amino acids-deleted canine hepatocyte growth factor are useful for the treatment of liver diseases, kidney diseases, lung diseases, digestive diseases, cardiocirculatory diseases or cranial nerve diseases.

The resent invention relates to nanovesicles derived from bacteria of genus Rhodococcus, and a use thereof. The present inventors experimentally ascertained that vesicles in clinical samples of patients with lung cancer, pancreatic cancer, bile duct cancer, breast cancer, bladder cancer, lymphoma, diabetes, stroke, myocardial infarction, asthma, COPD and dementia are significantly reduced compared to those of normal people, the secretion of inflammatory mediators by pathogenic vesicles such as E. coli-derived vesicles is significantly inhibited when the vesicles separated from the strain are administered, and vesicles derived from bacteria of the genus Rhodococcus significantly inhibit cranial nerve cell damage caused by stress hormones, and thus vesicles derived from bacteria of the genus Rhodococcus, according to the present invention, are expected to be effectively usable for the purpose of developing a method for diagnosing lung cancer, pancreatic cancer, bile duct cancer, breast cancer, bladder cancer, lymphoma, diabetes, stroke, myocardial infarction, asthma, COPD and / or dementia, and a composition for preventing or treating malignant disease, diabetes, stroke, cardiovascular disease, inflammatory lung disease, and / or cranial nerve diseases.

The present disclosure relates to a pharmaceutical composition for preventing or treating a cranial nerve disease, comprising a Fomes fomentarius extract, a fraction thereof, or a compound isolated therefrom as an active ingredient. According to the present disclosure, the Fomes fomentarius extract is included as an active ingredient so that there are significant effects of inhibiting the production or expression of inflammatory cytokines and improving the activity of glucose metabolism in the brain to prevent or treat cranial nerve diseases, of lowering side effects on the human body as a natural product, and of being easily prepared and ingested.

The invention relates to medical equipment, in particular to a microvascular decompression device for facial spasm cranial nerve diseases. The microvascular decompression device comprises a movable bedplate and a fixing frame vertically fixed on the movable bedplate; a fixing ring is mounted in the fixing frame through bolts; a restraining assembly for fixing the head of a patient is arranged on the fixing ring, wherein a driving mechanism connected with the restraining assembly is arranged below the movable bedplate; the driving mechanism comprises a self-locking transmission structure and a rotating structure connected with the self-locking transmission structure and the restraining assembly; the adjusting structure drives the movable bedplate, the restraining assembly arranged on the movable bedplate and the driving mechanism to swing so as to adjust the head of the patient to a proper operation position, the self-locking transmission structure drives the rotating structure to rotate after adjustment, and finally the rotating structure drives the restraining assembly to move to fix the head of the patient; and therefore, the patient is prevented from vibrating in the operation process, and the self-locking transmission structure can ensure that the clamping force of the restraining assembly is not loosened.

The present invention relates to vesicles derived from bacteria of the genus Deinococcus, and a use thereof. The present inventors experimentally ascertained that the vesicles in clinical samples of cancer, inflammatory disease and dementia patients are significantly more reduced than those in normal people, the secretion of inflammatory mediators by pathogenic vesicles such as E. coli-derived vesicles is significantly inhibited when the vesicles isolated from the strain are administered, and vesicles derived from bacteria of the genus Deinococcus significantly inhibit cranial nerve cell damage caused by stress hormones, and thus it is expected that vesicles derived from bacteria of the genus Deinococcus, according to the present invention, can be effectively used for the purpose of developing a method for diagnosing cancer, inflammatory diseases and / or dementia and a composition for preventing, alleviating or treating cancer, inflammatory diseases and / or cranial nerve diseases.

The present invention relates to a method of inducing differentiation into a 3D dopaminergic midbrain organoid using a specific electromagnetic wave. It was specifically identified that the method makes it possible to remarkably improve production efficiency of a dopaminergic neuronal 3D-differentiated organoid, from which symptoms of Parkinson's disease can be effectively alleviated. Thus, it is anticipated that the present invention is capable of making a more fundamental approach and achieving targeted therapies in the treatment of a cranial nerve disease.

Provided is a method of diagnosing or treating a disease in a subject using the vesicles derived from bacteria of the genus Rhodococcus. The vesicles are significantly decreased in a clinical sample obtained from a patient with lung cancer, pancreatic cancer, bile duct cancer, breast cancer, bladder cancer, lymphoma, diabetes, stroke, myocardial infarction, asthma, COPD, and dementia, compared with a normal individual, and administration of the vesicles to the patient inhibits the secretion of inflammation mediators caused by pathogenic vesicles such as E. coli-derived vesicles, and inhibits cranial nerve cell damage caused by stress hormones, therefore the vesicles are used in a method of diagnosing lung cancer, pancreatic cancer, bile duct cancer, breast cancer, bladder cancer, lymphoma, diabetes, stroke, myocardial infarction, asthma, COPD, and / or dementia, and a method of alleviating or treating a malignant disease, diabetes, stroke, a cardiovascular disease, an inflammatory pulmonary disease, and / or a cranial nerve disease.

A feline hepatocyte growth factor gene and a 15 base pairs-deleted feline hepatocyte growth factor gene. These genes encode the following protein (a) or (b): (a) a protein having an amino acid sequence shown in SEQ ID NO: 2 or 4; and (b) a protein having an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 2 or 4, and having a feline hepatocyte growth factor activity. The feline hepatocyte growth factor and the 5 amino acids-deleted feline hepatocyte growth factor are useful for the treatment of liver diseases, kidney diseases, lung diseases, digestive diseases, cardiocirculatory diseases or cranial nerve diseases.

The present invention relates to a novel quinazoline-2,4-dione derivative of formula (I), a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising a compound of formula (I) as an active ingredient for preventing or treating neurological brain disease.

Provided are vesicles derived from bacteria of the genus Deinococcus and a use thereof. The vesicles significantly decreased in a clinical sample obtained from a patient with cancer, an inflammatory disease, and dementia, compared with a normal individual, and when the vesicles isolated from the strain were administered, the secretion of inflammation mediators caused by pathogenic vesicles such as E. coli-derived vesicles was considerably inhibited, and vesicles derived from bacteria of the genus Deinococcus significantly inhibit cranial nerve cell damage caused by stress hormones, and therefore, the vesicles derived from bacteria of the genus Deinococcus according to the presently claimed subject matter may be effectively used to develop a method of diagnosing cancer, an inflammatory disease, and / or dementia, and a composition for preventing, alleviating, or treating cancer, an inflammatory disease, and / or a cranial nerve disease.

A device and method for treating cerebral diseases can be used for treating cerebral diseases such as hemiplegia, stroke, headache, cerebral palsy, sleep disorders, cerebrovascular diseases, cranial nerve diseases, cerebral functional diseases, encephalatrophy, dizziness, vegetative state and the like, and comprises a head contact part, a driving part and a base. The interiors of brain tissues are mutually massaged and extruded, so that the problems of some brain diseases are solved.

The invention relates to a cranial nerve disease treating device, which belongs to the technical field of medical appliance structures. The cranial nerve disease treating device comprises a head cap casing, wherein the head cap casing is made of magnetic-conductible medical stainless steel materials, a bottom plate made of stainless steel materials is arranged at the top part at the inner circumference of the head cap casing, a permanent magnet is sealed between the head cap casing and the bottom plate, and a dismountable medicine bag containing Chinese medicine powder is respectively arranged at the left side and the right side of the inner circumference of the head cap casing. The invention has reasonable structural design, combines the pure Chinese medicine with the magnetic therapy, and belongs to the cranial nerve disease treating device without toxic or side effects and high cure rate.